News

Nomic Partners with Novo Nordisk to Scale Proteomics for Drug Discovery

We’re excited to share that Nomic Bio, an AVANT BIO portfolio company, has partnered with Novo Nordisk to bring high-throughput, quantitative proteomics to their AI-enabled drug discovery platform.

Using Nomic’s nELISA™ platform, Novo will access proteomic data across up to 120,000 samples, accelerating target discovery through deeper biological insights.

Together, they’ll also co-develop the first proteomics platform purpose-built for drug discovery—a major step forward in making proteomics more scalable and impactful for next-gen therapeutics.

Visit Nomic’s site to learn more: https://nomic.bio/